Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
BOSTON, Mass. – May 2, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies. Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and its SeqImmune™ discovery module, which is a sequence-first workflow […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
— Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline — BOSTON, MA; November 17, 2022—Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]
ATX-Gx™ Biotech Licensee Discovering Novel Therapeutics
Dren Bio leveraged Alloy Therapeutics’ ATX-Gx™ humanized mouse platform and Discovery Services to successfully identify a high-quality lead candidate for its Enhanced ADCC Program. This partnership underscores the effectiveness of Alloy’s royalty-free licensing model and integrated discovery support in helping biotech startups rapidly advance oncology and autoimmune programs toward the clinic. Alloy has more than […]
Partnering with Target-Rich Biotech Companies
Alloy Therapeutics collaborates with “target-rich” biotech companies through its 82VS venture studio to launch asset-centric joint ventures that accelerate drug discovery. By providing end-to-end Discovery Services and company creation support, Alloy enables partners to produce high-value targets and move promising treatments toward the clinic without traditional capital constraints. Running a successful early-stage biotech company requires […]
Democratizing Access for Academic Entrepreneurs
We are advancing Alloy as a biotechnology ecosystem company, because we believe strongly that the innovation and breakthroughs that result from a network of relationships are far more powerful than those that can advance from silos. We collaborate with everyone to compete against disease. An exciting element of this dynamic is how under-resourced, smaller teams […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Alloy Therapeutics led a $7 million Series A for Mytide Therapeutics to scale its AI-enabled Gen2 platform, which uses machine learning to accelerate peptide manufacturing by 30x. This technology enables the rapid, high-purity production of complex natural and non-natural peptides for therapeutic discovery and personalized peptide vaccines (PPV). Biotech ecosystem company Alloy Therapeutics leads the […]